There were no clear differences in the frequency of ER+, PR+, and HER2+ disease by menopausal status, but few studies (two in North Africa; four in sub-Saharan Africa) were based on case series where ≥60% of the women were postmenopausal at breast cancer diagnosis (Table 3). Here, ERBB2 is linked to breast cancer.